Madrigal Pharmaceuticals, Inc. vs Johnson & Johnson
MDGL vs JNJ — side-by-side comparison from reported financials. MDGL leads 2, JNJ leads 6 of 8 comparable metrics.
Madrigal Pharmaceuticals, Inc.
MDGL · Healthcare
$471.75-1.08%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | MDGL | JNJ |
|---|---|---|
| Price | $471.75 | $261.79 |
| Market cap | $10.9B | $631B |
| Revenue (TTM) | $1.28B | $97.9B |
| Revenue growth | +149.0% | +5.6% |
| Net margin | -25.3% | 21.5% |
| Free cash flow | -$207M | $22.2B |
| Net cash (debt) | $644M | ($27.8B) |
| 1-year price return | +10.1% | +37.0% |
| P/E | — | 29.9 |
| P/E vs own history (cheap-side %) | — | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | -57% | 26% |
| Altman Z-score | 7.49 | — |
| CV checks passed | 5 of 9 | 10 of 9 |
| Employees | 915 | 140,800 |
Full résumé-style profiles: MDGL CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.